XML 68 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments
Presented below is financial information with respect to the Company’s reportable segments for the years presented:
Year Ended December 31,
202420232022
Segment revenues:
Software$180,365 $159,124 $135,578 
Drug discovery27,174 57,542 45,377 
Total segment revenues207,539 216,666 180,955 
Segment cost of revenues:
Software36,900 29,514 29,576 
Drug discovery38,556 46,460 50,357 
Total segment cost of revenues75,456 75,974 79,933 
Segment gross profit:
Software143,465 129,610 106,002 
Drug discovery(11,382)11,082 (4,980)
Total segment gross profit132,083 140,692 101,022 
Unallocated (expense) income:
Research and development(201,785)(181,766)(126,372)
Sales and marketing(39,917)(37,226)(30,642)
General and administrative(99,677)(99,148)(90,825)
Gain on equity investments— 147,213 11,825 
Change in fair value5,683 53,461 (18,084)
Other income17,902 19,693 3,953 
Income tax expense(1,412)(2,199)(63)
Consolidated net (loss) income$(187,123)$40,720 $(149,186)
Schedule of Revenues by Geographic Area
Revenues by geographic area are determined based on the address provided by the Company's customers and partners. The following table sets forth revenues by geographic area for the years ended December 31, 2024, 2023, and 2022:
Year Ended December 31,
202420232022
United States$114,869 $161,961 $123,556 
APAC25,802 24,569 21,680 
EMEA65,650 29,135 34,451 
Rest of World1,218 1,001 1,268 
$207,539 $216,666 $180,955